Bambang Very Enthusias Brilliance Abdillah Akbar
Research Subjects
Bambang Very Enthusias Brilliance Abdillah Akbar has a total of 14 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Isreb
School of Pharmacy and Biomedical Sciences, University of Central Lancashire, Preston, Lancashire, UK
2 shared publications - Andrea Gill
Paediatric Medicines Research Unit, Alder Hey Children’s NHS Foundation Trust, Liverpool, UK
2 shared publications - Cecile Ayako Dreiss
Institute of Pharmaceutical Science King's College London London UK
2 shared publications - Louise Bracken
Paediatric Medicines Research Unit Alder Hey Children's NHS Foundation Trust Liverpool UK
2 shared publications - Marcelo Alves da Silva
Department of Chemistry, University of Bath, Bath, UK
2 shared publications Mohamed A. Alhnan
2 shared publications
Latest Publications
- Open Access
- 7 August 2026
- Published by Elsevier in SSRN Electronic Journal
One Ink for Two Processes: Exploiting Rheology to Accelerate 3D-Printed Chewable Tablet Manufacturing
Personalised medicines are increasingly required in paediatric and hospital pharmacy practice, where licensed preparations may not be suitable. Semi-solid extrusion three-dimensional printing (SSE-3DP) enables the production of these patient-specific dosage forms, especially in chewable tablets. However, its layer-by-layer fabrication may limit manufacturing speed and routine implementation in time-pressured hospital pharmacy workflows. This study manufactured theophylline-loaded chewable gummy tablets via two routes: conventional SSE-3DP and template-based ink deposition (TID), using an identical printer and without the need for pharmaceutical ink reformulation. The ink was printed directly at a low temperature to produce cylindrical 3DP tablets, whereas TID extruded at a higher temperature into customised pyramidal template cavities. Rheological assessment of the ink under two processing conditions showed that temperature-dependent viscosity behaviour underpinned the distinct manufacturing routes. Following process optimisation, TID produced gummy tablets in 2-6 sec/unit, a 7-fold increase in process speed compared to 3DP (14-42 sec/unit). TID tablets met the pharmacopoeia requirements for weight and content uniformity, showed overall quality attributes comparable to those of 3DP, and remained stable for up to 28 days at 5°C and 25°C. However, the differing thermal and solidification rates of the two routes resulted in distinct drug-release profiles. Overall, this work extends the functionality of the 3D printer and demonstrates a practical strategy for converting the SSE-3DP process into a rapid dispensing workflow for small-batch personalised gummy medicines in hospital pharmacies and point-of-care settings.
- 7 August 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessOne Ink for Two Processes: Exploiting Rheology to Accelerate 3D-Printed Chewable Tablet Manufacturing
Personalised medicines are increasingly required in paediatric and hospital pharmacy practice, where licensed preparations may not be suitable. Semi-solid extrusion three-dimensional printing (SSE-3DP) enables the production of these patient-specific dosage forms, especially in chewable tablets. However, its layer-by-layer fabrication may limit manufacturing speed and routine implementation in time-pressured hospital pharmacy workflows. This study manufactured theophylline-loaded chewable gummy tablets via two routes: conventional SSE-3DP and template-based ink deposition (TID), using an identical printer and without the need for pharmaceutical ink reformulation. The ink was printed directly at a low temperature to produce cylindrical 3DP tablets, whereas TID extruded at a higher temperature into customised pyramidal template cavities. Rheological assessment of the ink under two processing conditions showed that temperature-dependent viscosity behaviour underpinned the distinct manufacturing routes. Following process optimisation, TID produced gummy tablets in 2-6 sec/unit, a 7-fold increase in process speed compared to 3DP (14-42 sec/unit). TID tablets met the pharmacopoeia requirements for weight and content uniformity, showed overall quality attributes comparable to those of 3DP, and remained stable for up to 28 days at 5°C and 25°C. However, the differing thermal and solidification rates of the two routes resulted in distinct drug-release profiles. Overall, this work extends the functionality of the 3D printer and demonstrates a practical strategy for converting the SSE-3DP process into a rapid dispensing workflow for small-batch personalised gummy medicines in hospital pharmacies and point-of-care settings.
- Open Access
- 3 February 2026
- Published by Elsevier in SSRN Electronic Journal
Accurate Low-Temperature Direct Extrusion 3D Printing of Personalised Paediatric Minitablets
Medicine individualisation remains constrained by the limited availability of age-appropriate strengths and by extemporaneous practices that can compromise dose consistency. Direct powder extrusion (DPE) 3D printing offers an alternative manufacturing method for personalised medicine, without introducing solvents, complex preparation, or post-processing that challenge pharmacy adoption. However, achieving uniform weight and drug content for small objects (e.g., paediatric-friendly minitablets) and lowering the preparation temperature remain challenges for extrusion-based 3D printing technologies.In this work, we introduce a facile low-temperature DPE 3D printing strategy to manufacture carvedilol minitablets, starting from carvedilol powder or licensed tablets as starting materials, using a high-precision pharmaceutical-grade 3D printer. Methacrylate-based polymers, polyethylene glycol, and glyceryl monostearate were used to enable extrusion at 70-75°C. When the 3D printer was challenged with minute-dimensional designs, it was possible to manufacture batches of minitablets up to 2 mm in diameter with 0.8 mm in thickness. The lowest minitablet weight variation was 1.48%, achieved with an optimal diameter of 3.6 mm and a thickness of 1.6 mm; this was also reflected in the drug content uniformity (within ±5%). The immediate-release batch met British Pharmacopoeia requirements (>80% in 45 min), whereas the extended-release formulations exhibited prolonged drug release (>50% in 24 h).These findings extend DPE 3D printing to a viable manufacturing platform for accurate, low-dose small solid units, such as minitablets. By coupling a GMP-compliant 3D printer with a simplified preparation workflow, this work provides a realistic blueprint for integrating DPE-enabled personalised minitablets into hospital pharmacy and point-of-care settings.
- 3 February 2026
- Published by Elsevier in SSRN Electronic Journal
Open AccessAccurate Low-Temperature Direct Extrusion 3D Printing of Personalised Paediatric Minitablets
Medicine individualisation remains constrained by the limited availability of age-appropriate strengths and by extemporaneous practices that can compromise dose consistency. Direct powder extrusion (DPE) 3D printing offers an alternative manufacturing method for personalised medicine, without introducing solvents, complex preparation, or post-processing that challenge pharmacy adoption. However, achieving uniform weight and drug content for small objects (e.g., paediatric-friendly minitablets) and lowering the preparation temperature remain challenges for extrusion-based 3D printing technologies.In this work, we introduce a facile low-temperature DPE 3D printing strategy to manufacture carvedilol minitablets, starting from carvedilol powder or licensed tablets as starting materials, using a high-precision pharmaceutical-grade 3D printer. Methacrylate-based polymers, polyethylene glycol, and glyceryl monostearate were used to enable extrusion at 70-75°C. When the 3D printer was challenged with minute-dimensional designs, it was possible to manufacture batches of minitablets up to 2 mm in diameter with 0.8 mm in thickness. The lowest minitablet weight variation was 1.48%, achieved with an optimal diameter of 3.6 mm and a thickness of 1.6 mm; this was also reflected in the drug content uniformity (within ±5%). The immediate-release batch met British Pharmacopoeia requirements (>80% in 45 min), whereas the extended-release formulations exhibited prolonged drug release (>50% in 24 h).These findings extend DPE 3D printing to a viable manufacturing platform for accurate, low-dose small solid units, such as minitablets. By coupling a GMP-compliant 3D printer with a simplified preparation workflow, this work provides a realistic blueprint for integrating DPE-enabled personalised minitablets into hospital pharmacy and point-of-care settings.